Table 3.
Clinical data of patients with negative serum and urine immunofixation at evaluation of response but not qualifying for aCR due to abnormal FLCR.
| Baseline | After 6 months of therapy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MC type | eGFR, mL/min | iFLC, mg/L | U-FLC, mg/L | dFLC, mg/L | FLCR | eGFR, mL/min | iFLC, mg/L | U-FLC, mg/L | dFLC, mg/L | FLCR | |
| ID1 | LC-λ | 77 | 96 | 2.00 | 94 | 0.02 | 71 | 18 | 1.26 | 17 | 0.07 |
| ID2 | LC-λ | 81 | 47 | 11.75 | 36 | 0.25 | 45 | 8 | 1.92 | 6 | 0.24 |
| ID3 | IgAλ | 75 | 102 | 6.12 | 95 | 0.06 | 106 | 8 | 1.12 | 7 | 0.14 |
| ID4 | LC-κ | 51 | 612 | 19.00 | 593 | 32 | 77 | 8 | 3.68 | 5 | 2.17 |
MC monoclonal component type, LC light chain, eGFR estimated glomerular filtration rate, iFLC involved free light chain, dFLC difference between involved and uninvolved free light chains, FLCR free light chain ratio, U-FLC uninvolved FLC.